GoodRx (NASDAQ:GDRX) Trading Down 7.5% – Here’s What Happened

GoodRx Holdings, Inc. (NASDAQ:GDRX)’s stock price traded down 7.5% on Friday . The stock traded as low as $4.18 and last traded at $4.22. 1,135,327 shares were traded during mid-day trading, a decline of 20% from the average session volume of 1,422,404 shares. The stock had previously closed at $4.56.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. UBS Group dropped their price objective on shares of GoodRx from $9.00 to $8.50 and set a “neutral” rating for the company in a research note on Friday, August 9th. Citigroup decreased their price target on shares of GoodRx from $10.00 to $7.00 and set a “buy” rating for the company in a research report on Wednesday. Royal Bank of Canada reissued an “outperform” rating and issued a $10.00 price objective on shares of GoodRx in a research note on Friday, August 16th. Barclays lowered their target price on GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a research report on Monday. Finally, Raymond James upgraded GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price target on the stock in a research report on Friday, August 9th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, GoodRx has an average rating of “Moderate Buy” and a consensus target price of $8.86.

GoodRx Stock Performance

The stock has a market cap of $1.57 billion, a price-to-earnings ratio of -139.67, a P/E/G ratio of 3.22 and a beta of 1.39. The company’s fifty day simple moving average is $6.62 and its two-hundred day simple moving average is $7.44. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48.

Insider Buying and Selling

In other news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.86, for a total value of $83,921.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 4.17% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On GoodRx

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Jupiter Asset Management Ltd. purchased a new position in GoodRx in the first quarter worth $707,000. Liontrust Investment Partners LLP purchased a new position in shares of GoodRx in the 2nd quarter worth about $520,000. Raymond James & Associates grew its position in GoodRx by 212.6% during the third quarter. Raymond James & Associates now owns 394,006 shares of the company’s stock valued at $2,734,000 after buying an additional 267,951 shares during the period. Legato Capital Management LLC purchased a new stake in GoodRx during the second quarter worth about $805,000. Finally, Swiss National Bank raised its position in GoodRx by 3.9% in the first quarter. Swiss National Bank now owns 155,000 shares of the company’s stock worth $1,100,000 after acquiring an additional 5,800 shares during the period. Hedge funds and other institutional investors own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.